|
Paul E. Freiman is Chairman of the Board of Penwest. He is also President and Chief Executive Officer of Neurobiological Technologies, Inc. (NTI). He is the former Chairman and Chief Executive Officer of Syntex Corporation (Syntex), where he had a long and successful career and was instrumental in the sale of Syntex to Roche Holdings for $5.3 billion. He is credited with much of the marketing success of Syntex's lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed by Proctor & Gamble as Aleve. Mr. Freiman currently serves as chairman of the board of SciGen Pte. Ltd. and also serves on the boards of Calypte Biomedical Corporation, NeoPharm Inc., NovaCal Pharmaceuticals, PHYTOS Inc. and Otsuka America Pharmaceuticals, Inc. He has been chairman of the Pharmaceutical Manufacturers of America Association (PhRMA) and has also chaired a number of key PhRMA committees. Mr. Freiman holds a B.S. degree from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy. | 